Nationwide Commercial Laboratory Seroprevalence Survey
Description
CDC is working with commercial laboratories to conduct large-scale geographic seroprevalence surveys to estimate the percentage of people who were previously infected with SARS-CoV-2, the virus that causes COVID-19 disease. The strategy involves working with state, local, territorial, academic, and commercial partners to better understand COVID-19 in the United States using serology (antibody) testing for surveillance (“seroprevalence surveys” or “serosurveys”). For the surveys, de-identified clinical blood samples are tested for antibodies to SARS-CoV-2.
This dataset contains the data used to by the Nationwide Commercial Laboratory Seroprevalence Survey interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#national-lab.
Additional information is available at https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html.
Resources
| Name |
Format |
Description |
Link |
|
40 |
|
https://data.cdc.gov/api/views/d2tw-32xv/rows.rdf?accessType=DOWNLOAD |
|
23 |
|
https://data.cdc.gov/api/views/d2tw-32xv/rows.json?accessType=DOWNLOAD |
|
55 |
|
https://data.cdc.gov/api/views/d2tw-32xv/rows.xml?accessType=DOWNLOAD |
|
8 |
|
https://data.cdc.gov/api/views/d2tw-32xv/rows.csv?accessType=DOWNLOAD |
Tags
- seroprevalence
- covid19
- coronavirus
- laboratory
- prevalence
- covid
- serosurveys
- covid-19